People · Operator
Named in public records as an officer, director or promoter · active 2010–2022 · Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Modernizing Medicine, Inc. | — | Other | Series D+ | $341.0M | $725.4M | 2010 |
Michael Sherling at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Sherling on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Amr Kronfol | 1 | 5 |
| Andrew Park | 1 | 5 |
| Gina Loften | 1 | 4 |
| Mark deLaar | 1 | 4 |
| Gary Steele | 1 | 3 |
| Barry Mosheim | 1 | 3 |
| JAMES BROOKS | 1 | 2 |
| Daniel Cane | 1 | 2 |
| Phillip Pead | 1 | 1 |
| Michelle Scheer | 1 | 1 |
| Jean Bua | 1 | 1 |
| Fred Hassan | 1 | 1 |
| Rick Von Pusch | 1 | 1 |
| Mark Fleisher | 1 | 1 |
| Karen O'Byrne | 1 | 1 |
| Michael Sherling, M.D. | 1 | 1 |
| Robert Nagro | 1 | 1 |
| Patric Edmondson | 1 | 1 |
| Brad Rennick | 1 | 1 |
| Joseph Harpaz | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.